

Table 4: Estimated effect of HIP programme on primary and secondary outcomes
Per protocol 1: HIP group = HIP administered at baseline

Measure		HIP Mean (sd)	TAU Mean (sd)	Effect^a (95% CI) (adjusted for baseline) P =	Intra class correlation
SF36v2					
n patients		32	61		
K nurses		15	24		
SF36v2 PCS	Baseline ^b	44.2(12.6)	45.0(10.1)	1.01(-2.7,4.8)	-0.073
	53 Weeks	45.5(12.6)	45.0(10.8)	P=0.594	
SF36v2 MCS	Baseline ^b	39.5(14.4)	38.0(14.1)	2.32(-3.5,8.2)	0.028
	53 Weeks	40.9(15.0)	37.9(14.7)	P=0.438	
EQ5D VAS					
n patients		33	62		
k nurses		15	24		
EQ5D VAS	Baseline ^b	60.9(23.1)	60.8(19.1)	6.09(-2.6,14.7)	0.194
	53 Weeks	63.5(20.2)	57.5(20.9)	P=0.170	
EQ5D					
N patients		34	58		
K nurses		15	24		
EQ5D	Baseline ^b	0.654(0.310)	0.619(0.330)	0.000(-0.11,0.11)	-0.039
	53 Weeks	0.622(0.354)	0.600(0.315)	P=0.997	